Long-term outcomes of surgical treatment of common ovarian cancer at the stage of primary debulking

Background. Comparative assessment of the long-term oncological results of extended, combined and standard surgical interventions.

Materials and methods. The study included women with histologically verified ovarian cancer T3—4N0—1M0—1. Group A (experimental) patients underwent advanced and combined surgical interventions; group B (control) patients underwent standard surgical interventions. In the postoperative period, all patients received 6 courses of polychemotherapy with a combination of platinum and taxanes. The authors compared the frequency of achieving optimal and conditionally radical operations after performing extended and combined operations and standard surgical interventions, the structure, frequency and causes of intra- and postoperative complications, and overall and disease-free survival.

Results. From 2010 to 2018, we selected 150 archived case histories of patients with advanced ovarian cancer (III-IV stages). 135 (90 %) patients were able to track the long-term results of treatment. In group A (experimental), complete debulking was achieved in 52.8 %, in group B (control) — 26.7 %. In group A, 6 (19.9 %) patients had postoperative complications of I-II degree of severity, 1 patient had postoperative complications of IIIA degree of severity, complications of IIIB-IV degree of severity in the study group did not occur (p = 0.05). In group B, intraoperative complications were observed in 27 (22.5 %) patients. Postoperative I—II degrees of severity were observed in 28 (23.3 %) patients, III—IV degrees of severity — in 8 (6.6 %). In group B, the overall survival rate was 54.7 months, and re¬lapse-free was 14.3 months, in group A — 79.2 months and 19 months respectively (p = 0.004 and <0.05).

Conclusions. The method of choosing treatment for patients with advanced ovarian cancer in the first stage is surgery in the amount of com - plete debulking. Performing combined and advanced operations for advanced ovarian cancer affects the success of complete debulking and is reasonable.

1. Horowitz N.S., Larry M.G., Miller A. et al. Predictive modeling for determination of microscopic residual disease at primary cytoreduction: an NRG Oncology/ Gynecologic Oncology Group 182 Study. Gynecol Oncol 2018;148(1):49—55. DOI: 10.1016/j.ygyno.2017.10.011.

2. Whitney C.W., Spirtos N. Gynecologic Oncology Group Surgical Procedures Manual. Philadelphia: Gynecologic Oncology Group, 2010.

3. Peiretti M., Zanagnolo V., Aletti G.D. et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. Single institution experience. Gynecol Oncol 2010;119(2):259—64. DOI: 10.1016/j.ygy-no.2010.07.032.

4. Mueller J.J., Zhou Q.C., Iasonos A. et al. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. Gynecol Oncol 2016;140(3):436—42. DOI: 10.1016/j.ygyno.2016.01.008.

5. Wallace S., Kumar A., Mc Gree M., Weav¬er A. Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible. Gynecol Oncol 2017;145(1):21—6. DOI: 10.1016/j.ygyno.2017.01.029.

6. Bristow R.E., del Carmen M.G., Kaufman H.S., Montz FJ. Radical oophorectomy with primary stapled colorectal anastomosis for resection of locally advanced epithelial ovarian cancer. J Am Coll Surg 2003;197(4):565—74. DOI: 10.1016/S1072-7515(03)00478-2.

7. Sznurkowski JJ. En bloc pelvic resection for advanced ovarian cancer preceded by central ligation of vessels supplying the tumor bed: a description of surgical technique and a feasibility study. World J Surg Oncol 2016;14:133. DOI: 10.1186/s12957-016-0894-5.

8. Vergote I., Trope C.G., Amant F. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943-53.

9. Kehoe S., Hook J., Nankivell M. et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-infe-riority trial. Lancet 2015;386(9990): 249-57. DOI: 10.1016/S0140-6736(14)62223-6.